NCT07923305
Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Proportion of participants with iCVID who meet any responder definitions
Timeframe: At Week 32
Secondary (6)
Change from baseline in FACIT-Fatigue total score at Week 24 in Part A and Week 32 in Part B
Percent change from baseline in FVC% predicted at Week 32
Percent change from baseline in diffusing capacity of the lung for carbon monoxide at Week 32
Change from baseline in FACIT-dyspnea severity score at Week 24 in Part A and Week 32 in Part B
Change from baseline in time spend in moderate to vigorous physical activity measured with a wearable device
Show 1 moreShow less
Incidence of treatment-emergent adverse events (TEAE), serious AEs (SAE), TEAE leading to permanent discontinuation, adverse events of special interest (AESI)
Arms and interventions
rilzabrutinibExperimental
rilzabrutinib
placeboPlacebo comparator
placebo
Drugs: rilzabrutinib, placebo